Also published as: A Ram Kim, Ae-Jung Kim, Ah-Ram Kim, Albert H Kim, Alison J Kim, Andrea J Kim, Angela H Kim, Angela Kim, Angela S Kim, Anna Kim, Anthony S Kim, Aram Kim, Arie Kim, B T Kim, B-Y Kim, Baek Kim, Beom-Jun Kim, Beomsoo Kim, Beomsu Kim, Bo Ri Kim, Bo Young Kim, Bo-Eun Kim, Bo-Ra Kim, Bo-Rahm Kim, Bomi Kim, Bong-Jo Kim, Bongjun Kim, Boo-Young Kim, Borahm Kim, Boram Kim, Brandon J Kim, Brian S Kim, Byeong-Won Kim, Byoung Jae Kim, Byron Kim, Byung Guk Kim, Byung Jin Kim, Byung-Chul Kim, Byung-Gyu Kim, Byung-Taek Kim, Byungwook Kim, C H Kim, Carla F Kim, Caroline Kim, Cecilia E Kim, Cecilia Kim, Chae-Hyun Kim, Chan Wook Kim, Chan-Duck Kim, Chan-Hee Kim, Chan-Wha Kim, Chang Seong Kim, Chang-Gu Kim, Chang-Yub Kim, Chanhee Kim, Cheol-Hee Kim, Cheol-Su Kim, Cheorl-Ho Kim, Choel Kim, Chong Ae Kim, Chong Kook Kim, Chongtae Kim, Choon Ok Kim, Choon-Song Kim, Chu-Young Kim, Chul Hoon Kim, Chul Hwan Kim, Chul-Hong Kim, Chunki Kim, D-W Kim, Da Sol Kim, Da-Hyun Kim, Da-Sol Kim, Dae Hyun Kim, Dae In Kim, Dae Keun Kim, Dae-Eun Kim, Dae-Jin Kim, Dae-Kyeong Kim, Dae-Kyum Kim, Dae-Soo Kim, Daeeun Kim, Daegyeom Kim, Daeseung Kim, Daesik Kim, Daham Kim, Dahee Kim, Dakyung Kim, Dan Say Kim, David E Kim, Dayoung Kim, Dennis Y Kim, Deok Ryong Kim, Deok-Ho Kim, Deokhoon Kim, Do Hyung Kim, Do Yeon Kim, Do-Hyung Kim, Do-Kyun Kim, Dokyoon Kim, Don-Kyu Kim, Dong Gwang Kim, Dong Ha Kim, Dong Hyun Kim, Dong Il Kim, Dong Joon Kim, Dong Wook Kim, Dong-Eun Kim, Dong-Hee Kim, Dong-Hoon Kim, Dong-Hyeok Kim, Dong-Hyun Kim, Dong-Ik Kim, Dong-Kyu Kim, Dong-Seok Kim, Dong-Wook Kim, Dong-Yi Kim, Dong-il Kim, Donghee Kim, Donghyeon Kim, Donghyun Kim, Dongjoon Kim, Dongkyun Kim, Dongwoo Kim, Doo Yeon Kim, Doo Yeong Kim, Doyeon Kim, Duck-Hee Kim, E Kim, E-S Kim, Edwin H Kim, Eiru Kim, Elizabeth H Kim, Ellen Kim, Eonmi Kim, Eosu Kim, Eric Eunshik Kim, Eric Kim, Esl Kim, Esther Kim, Eui Hyun Kim, Eui Jin Kim, Eui-Soon Kim, Eun Hee Kim, Eun Ho Kim, Eun Ji Kim, Eun Kim, Eun Young Kim, Eun-Jin Kim, Eun-Joo Kim, Eun-Jung Kim, Eun-Kyung Kim, Eunae Kim, Eung Yeop Kim, Eung-Gook Kim, Eungseok Kim, Eunha Kim, Eunhyun Kim, Eunjoon Kim, Eunju Kim, Eunkyeong Kim, Eunmi Kim, Gahyun Kim, Geun-Young Kim, Gi Beom Kim, Gibae Kim, Gitae Kim, Go Woon Kim, Goo-Young Kim, Goun Kim, Grace Kim, Gu-Hwan Kim, Gukhan Kim, Gunhee Kim, Gwang Sik Kim, Gwangil Kim, Gye Lim Kim, Gyeonghun Kim, Gyudong Kim, H Kim, H S Kim, Ha-Jung Kim, Ha-Neui Kim, Hae Won Kim, Haein Kim, Haelee Kim, Haeryoung Kim, Hail Kim, Han Gyung Kim, Han Young Kim, Han-Kyul Kim, Hana Kim, Hanah Kim, Hang-Rai Kim, Hannah Kim, Hark Kyun Kim, Hee Jeong Kim, Hee Jin Kim, Hee Jong Kim, Hee Nam Kim, Hee Su Kim, Hee Young Kim, Hee-Jin Kim, Hee-Sun Kim, Heebal Kim, Heegoo Kim, Heejin Kim, Hei Sung Kim, Helen B Kim, Helen Kim, Heung-Joong Kim, Ho Shik Kim, Ho-Sook Kim, Hoguen Kim, Hong Sug Kim, Hong-Gi Kim, Hong-Hee Kim, Hong-Kook Kim, Hong-Kyu Kim, Hoon Kim, Hoon Seok Kim, Howard H Kim, Hwa-Jung Kim, Hwajung Kim, Hwi Seung Kim, Hwijin Kim, Hye Jin Kim, Hye Ran Kim, Hye Ree Kim, Hye Young Kim, Hye Yun Kim, Hye-Jin Kim, Hye-Jung Kim, Hye-Ran Kim, Hye-Sung Kim, Hye-Yeon Kim, Hye-Young H Kim, Hyejin Kim, Hyelim Kim, Hyemin Kim, Hyeon Ho Kim, Hyeon Jeong Kim, Hyeon-Ah Kim, Hyeong Hoe Kim, Hyeong Su Kim, Hyeong-Geug Kim, Hyeong-Jin Kim, Hyeong-Rok Kim, Hyeong-Taek Kim, Hyeonwoo Kim, Hyeseon Kim, Hyesung Kim, Hyeung-Rak Kim, Hyeyoon Kim, Hyeyoung Kim, Hyo Jong Kim, Hyo Jung Kim, Hyo-Soo Kim, Hyojin Kim, Hyojung Kim, Hyoun Ju Kim, Hyoun-Ah Kim, Hyoung Kyu Kim, Hyuk Soon Kim, Hyun Eun Kim, Hyun Gi Kim, Hyun Joon Kim, Hyun Ju Kim, Hyun Kim, Hyun Sil Kim, Hyun Soo Kim, Hyun Sook Kim, Hyun-Ji Kim, Hyun-Jin Kim, Hyun-Jung Kim, Hyun-Kyong Kim, Hyun-Sic Kim, Hyun-Soo Kim, Hyun-Yi Kim, Hyun-Young Kim, Hyun-ju Kim, Hyunbae Kim, Hyung Bum Kim, Hyung Hoi Kim, Hyung Min Kim, Hyung Yoon Kim, Hyung-Goo Kim, Hyung-Gu Kim, Hyung-Jun Kim, Hyung-Mi Kim, Hyung-Ryong Kim, Hyung-Seok Kim, Hyung-Sik Kim, Hyung-Suk Kim, Hyungjun Kim, Hyungkuen Kim, Hyungsoo Kim, Hyunjin Kim, Hyunjoon Kim, Hyunju Kim, Hyunki Kim, Hyunmi Kim, Hyunsoo Kim, Hyunwoo Kim, Hyunwook Kim, Hyunyoung Kim, Ick Young Kim, Il-Chan Kim, Il-Man Kim, Il-Sup Kim, In Ja Kim, In Joo Kim, In Kyoung Kim, In Su Kim, In Suk Kim, In-Hoo Kim, J H Kim, J Julie Kim, J Y Kim, Jae Bum Kim, Jae Geun Kim, Jae Gon Kim, Jae Hoon Kim, Jae Hun Kim, Jae Hyoung Kim, Jae Hyun Kim, Jae Seon Kim, Jae Suk Kim, Jae T Kim, Jae-Ick Kim, Jae-Jun Kim, Jae-Jung Kim, Jae-Min Kim, Jae-Ryong Kim, Jae-Yong Kim, Jae-Yoon Kim, Jae-Young Kim, Jaegil Kim, Jaehoon Kim, Jaemi Kim, Jaeuk U Kim, Jaewon Kim, Jaeyeon Kim, Jaeyoon Kim, Jang Heub Kim, Jang-Hee Kim, Jason K Kim, Jason Kim, Jayoun Kim, Jee Ah Kim, Jeeho Kim, Jeewoo Kim, Jeeyoung Kim, Jeffrey J Kim, Jeffrey Kim, Jenny H Kim, Jeong Hee Kim, Jeong Kyu Kim, Jeong Su Kim, Jeong-Han Kim, Jeong-Min Kim, Jeonghan Kim, Jeongseon Kim, Jeongseop Kim, Jeri Kim, Jessica Kim, Jewoo Kim, Ji Eun Kim, Ji Hun Kim, Ji Hye Kim, Ji Hyun Kim, Ji Won Kim, Ji Yeon Kim, Ji Young Kim, Ji-Dam Kim, Ji-Eun Kim, Ji-Hoon Kim, Ji-Man Kim, Ji-Won Kim, Ji-Woon Kim, Ji-Young Kim, Ji-Yul Kim, Ji-Yun Kim, Jieun Kim, Jiha Kim, Jiho Kim, Jihoon Kim, Jihye Kim, Jihyun Kim, Jimi Kim, Jin Cheon Kim, Jin Gyeom Kim, Jin Hee Kim, Jin Kim, Jin Kyong Kim, Jin Man Kim, Jin Seok Kim, Jin Won Kim, Jin Woo Kim, Jin Young Kim, Jin-Chul Kim, Jin-Soo Kim, Jina Kim, Jinhee Kim, Jinho Kim, Jinkyeong Kim, Jinsoo Kim, Jinsu Kim, Jinsup Kim, Jisook Kim, Jisu Kim, Jisun Kim, Jisup Kim, Jiwon Kim, Jiyea Kim, Jiyeon Kim, Jong Deog Kim, Jong Geun Kim, Jong Han Kim, Jong Heon Kim, Jong Ho Kim, Jong Hwan Kim, Jong Won Kim, Jong Woo Kim, Jong Yeol Kim, Jong-Ho Kim, Jong-Hyun Kim, Jong-Il Kim, Jong-Joo Kim, Jong-Ki Kim, Jong-Kyu Kim, Jong-Oh Kim, Jong-Seo Kim, Jong-Seok Kim, Jong-Won Kim, Jong-Yeon Kim, Jong-Youn Kim, JongKyong Kim, Jongchan Kim, Jonggeol J Kim, Jonggeol Jeffrey Kim, Jongho Kim, Jongkyu Kim, Jongmyung Kim, Jongwan Kim, Jooho Kim, Joon Kim, Joong Sun Kim, Joong-Seok Kim, Joonki Kim, Joonseok Kim, Joonyoung Kim, Joonyoung R Kim, Joori Kim, Joseph C Kim, Joseph Han Sol Kim, Joung Sug Kim, Joungmok Kim, Ju Deok Kim, Ju Han Kim, Ju Young Kim, Ju-Kon Kim, Ju-Ryoung Kim, Ju-Wan Kim, Juhyun Kim, Jun Chul Kim, Jun Hee Kim, Jun Hoe Kim, Jun Pyo Kim, Jun Seok Kim, Jun Suk Kim, Jun W Kim, Jun-Hyung Kim, Jun-Mo Kim, Jun-Sik Kim, June Hee Kim, June Soo Kim, June-Bum Kim, Junesun Kim, Jung Dae Kim, Jung H Kim, Jung Hee Kim, Jung Ho Kim, Jung Ki Kim, Jung Oh Kim, Jung Soo Kim, Jung Sun Kim, Jung-Ha Kim, Jung-Hyun Kim, Jung-In Kim, Jung-Lye Kim, Jung-Taek Kim, Jung-Woong Kim, JungMin Kim, Jungeun Kim, Jungsu Kim, Jungwoo Kim, Juyeong Kim, Juyong B Kim, Juyoung Kim, K-K Kim, K-S Kim, Kahye Kim, Kang Ho Kim, Kangjoon Kim, Kee-Pyo Kim, Kee-Tae Kim, Kellan Kim, Keun You Kim, Kevin K Kim, Ki Hyun Kim, Ki Kwon Kim, Ki Tae Kim, Ki Woong Kim, Kil-Nam Kim, Kiyoung Kim, Kook Hwan Kim, Kwan Hyun Kim, Kwan-Suk Kim, Kwang Dong Kim, Kwang Pyo Kim, Kwang-Eun Kim, Kwang-Pyo Kim, Kwangho Kim, Kwangwoo Kim, Kwonseop Kim, Kye Hun Kim, Kye Hyun Kim, Kye-Seong Kim, Kyeong Jin Kim, Kyeong-Min Kim, Kyeongjin Kim, Kyeongmi Kim, Kyong Min Kim, Kyong-Tai Kim, Kyoung Hoon Kim, Kyoung Hwan Kim, Kyoung Oh Kim, Kyoungtae Kim, Kyu-Kwang Kim, Kyuho Kim, Kyung An Kim, Kyung Do Kim, Kyung Han Kim, Kyung Hee Kim, Kyung Mee Kim, Kyung Sup Kim, Kyung Woo Kim, Kyung-Chang Kim, Kyung-Hee Kim, Kyung-Sub Kim, Kyung-Sup Kim, Kyunga Kim, Kyunggon Kim, Kyungjin Kim, Kyungsook Kim, Kyungtae Kim, Kyungwon Kim, Leen Kim, Leo A Kim, Leo Kim, Lia Kim, Luke Y Kim, M J Kim, M Kim, M V Kim, Maya Kim, Meelim Kim, Meesun Kim, Mi Jeong Kim, Mi Kyung Kim, Mi Ok Kim, Mi Ra Kim, Mi Young Kim, Mi-Hyun Kim, Mi-Na Kim, Mi-Sung Kim, Mi-Yeon Kim, Mi-Young Kim, Mijeong Kim, Mijung Kim, Min Bum Kim, Min Cheol Kim, Min Chul Kim, Min Joo Kim, Min Ju Kim, Min Jung Kim, Min Kim, Min Kyeong Kim, Min Seo Kim, Min Soo Kim, Min Wook Kim, Min-A Kim, Min-Gon Kim, Min-Hyun Kim, Min-Seo Kim, Min-Seon Kim, Min-Sik Kim, Min-Sun Kim, Min-Young Kim, Mina K Kim, Minah Kim, Minchul Kim, Minhee Kim, Minjae Kim, Minjeong Kim, Minji Kim, Minjoo Kim, Minju Kim, Minkyeong Kim, Minkyung Kim, Minseon Kim, Minsik Kim, Minsoon Kim, Minsu Kim, Minsuk Kim, Miri Kim, Miso Kim, Misu Kim, Misun Kim, Misung Kim, Moo-Yeon Kim, Moon Suk Kim, Myeong Ji Kim, Myeong Ok Kim, Myeong-Kyu Kim, Myeoung Su Kim, Myoung Hee Kim, Myoung Ok Kim, Myoung Sook Kim, Myung Jin Kim, Myung-Jin Kim, Myung-Sun Kim, Myung-Sunny Kim, Myungshin Kim, Myungsuk Kim, Na Yeon Kim, Na-Kuang Kim, Na-Young Kim, Nam Hee Kim, Nam-Eun Kim, Nam-Ho Kim, Nam-Hyung Kim, NamDoo Kim, NamHee Kim, Namkyoung Kim, Namphil Kim, Nan Young Kim, Nari Kim, Ngoc Thanh Kim, Ngoc-Thanh Kim, Oc-Hee Kim, Oh Yoen Kim, Ohn Soon Kim, Ok Jin Kim, Ok-Hwa Kim, Ok-Hyeon Kim, Ok-Kyung Kim, Okhwa Kim, Paul H Kim, Paul Kim, Paul T Kim, Peter K Kim, Reuben H Kim, Richard B Kim, Richard Kim, Rokki Kim, Rosalind Kim, Ryung S Kim, S Kim, S Y Kim, Sae Hun Kim, Saerom Kim, Sang Chan Kim, Sang Eun Kim, Sang Geon Kim, Sang Hyuk Kim, Sang Jin Kim, Sang Ryong Kim, Sang Soo Kim, Sang Wun Kim, Sang-Gun Kim, Sang-Hoon Kim, Sang-Min Kim, Sang-Tae Kim, Sang-Woo Kim, Sang-Young Kim, Sangchul Kim, Sangmi Kim, Sangsoo Kim, Sangwoo Kim, Scott Y H Kim, Se Hyun Kim, Se-Wha Kim, Sejoong Kim, Seohyeon Kim, Seohyun Kim, Seok Won Kim, Seokhwi Kim, Seokjoong Kim, Seol-A Kim, Seon Hee Kim, Seon Hwa Kim, Seon-Kyu Kim, Seon-Young Kim, Seong Jun Kim, Seong Kim, Seong-Hyun Kim, Seong-Ik Kim, Seong-Jin Kim, Seong-Min Kim, Seong-Seop Kim, Seong-Tae Kim, Seonggon Kim, Seongho Kim, Seongmi Kim, Seonhee Kim, Seoyeon Kim, Seoyoung Kim, Serim Kim, Seul Young Kim, Seul-Ki Kim, Seulhee Kim, Seung Chul Kim, Seung Jun Kim, Seung Tea Kim, Seung Won Kim, Seung Woo Kim, Seung-Jin Kim, Seung-Ki Kim, Seung-Whan Kim, Seungsoo Kim, Sewoon Kim, Shi-Mun Kim, Shin Kim, Sin Gon Kim, Sinai Kim, So Ree Kim, So Yeon Kim, So Young Kim, So-Hee Kim, So-Woon Kim, So-Yeon Kim, Soee Kim, Soeun Kim, Sohee Kim, Sol Kim, Song-Rae Kim, Soo Hyun Kim, Soo Jung Kim, Soo Wan Kim, Soo Whan Kim, Soo Yoon Kim, Soo Young Kim, Soo-Hyun Kim, Soo-Rim Kim, Soo-Youl Kim, SooHyeon Kim, Sook Young Kim, Soon Hee Kim, Soon Sun Kim, Soon-Hee Kim, Soriul Kim, Soung Jung Kim, Sowon Kim, Soyeong Kim, Steve Kim, Stuart K Kim, Su Jin Kim, Su Kang Kim, Su-Hyeong Kim, Su-Jeong Kim, Su-Jin Kim, Su-Yeon Kim, Suhyun Kim, Suhyung Kim, Suji Kim, Sujin Kim, Sujung Kim, Suk Jae Kim, Suk-Jeong Kim, Suk-Kyung Kim, Sukjun Kim, Sun Hee Kim, Sun Hye Kim, Sun Woong Kim, Sun Yeou Kim, Sun-Gyun Kim, Sun-Hee Kim, Sun-Hong Kim, Sun-Joong Kim, Sung Eun Kim, Sung Han Kim, Sung Hyun Kim, Sung Kyun Kim, Sung Mok Kim, Sung Soo Kim, Sung Tae Kim, Sung Won Kim, Sung Woo Kim, Sung Yeol Kim, Sung Young Kim, Sung-Bae Kim, Sung-Eun Kim, Sung-Hee Kim, Sung-Hoon Kim, Sung-Hou Kim, Sung-Jo Kim, Sung-Kyu Kim, Sung-Mi Kim, Sung-Wan Kim, Sunggun Kim, Sunghak Kim, Sunghoon Kim, Sunghun Kim, Sunghwan Kim, Sungjoo Kim, Sungmin Kim, Sungrae Kim, Sungryong Kim, Sungup Kim, Sungyeon Kim, Sungyun Kim, Sunkyu Kim, Sunoh Kim, Sunyoung Kim, Susy Kim, Sydney Y Kim, Tae Hoen Kim, Tae Hoon Kim, Tae Hun Kim, Tae Hyun Kim, Tae Il Kim, Tae Jin Kim, Tae Min Kim, Tae Wan Kim, Tae-Eun Kim, Tae-Gyu Kim, Tae-Hyoung Kim, Tae-Hyun Kim, Tae-Mi Kim, Tae-Min Kim, Tae-Woon Kim, Tae-You Kim, TaeHyung Kim, TaeYeong Kim, Taeeun Kim, Taehyeung Kim, Taehyoun Kim, Taeil Kim, Taejung Kim, Taek-Kyun Kim, Taek-Yeong Kim, Taewan Kim, Taeyoung Kim, Tai Kyoung Kim, Un Gi Kim, Un-Kyung Kim, Vladimir Kim, Wanil Kim, William Kim, Won Dong Kim, Won Ho Kim, Won J Kim, Won Jeoung Kim, Won Kim, Won Kon Kim, Won Kyung Kim, Won Seok Kim, Won Tae Kim, Won-Tae Kim, Wondong Kim, Woo Jin Kim, Woo Kim, Woo Kyung Kim, Woo Sik Kim, Woo-Jin Kim, Woo-Kyun Kim, Woo-Shik Kim, Woo-Yang Kim, Woojin Scott Kim, Wook Kim, Woong-Ki Kim, Woonhee Kim, Wootae Kim, Wun-Jae Kim, Y A Kim, Y S Kim, Y-D Kim, Y-M Kim, Yangseok Kim, Ye-Ri Kim, Yeaseul Kim, Yeeun Kim, Yeji Kim, Yejin Kim, Yekaterina Kim, Yeon Ju Kim, Yeon-Hee Kim, Yeon-Jeong Kim, Yeon-Jung Kim, Yeon-Ki Kim, Yeong-Sang Kim, Yeonhwa Kim, Yeonjung Kim, Yeonsoo Kim, Yerin Kim, Yeseul Kim, Yeul Hong Kim, Yo-Han Kim, Yong Deuk Kim, Yong Kwan Kim, Yong Kyun Kim, Yong Kyung Kim, Yong Sig Kim, Yong Sik Kim, Yong Sook Kim, Yong Sung Kim, Yong-Hoon Kim, Yong-Lim Kim, Yong-Ou Kim, Yong-Sik Kim, Yong-Soo Kim, Yong-Wan Kim, Yong-Woon Kim, Yongae Kim, Yongjae Kim, Yongkang Kim, Yongmin Kim, Yoo Ri Kim, Yoojin Kim, Yoon Sook Kim, Yoongeum Kim, Yoonjung Kim, You Sun Kim, You-Jin Kim, You-Sun Kim, Youbin Kim, Youn Shic Kim, Youn-Jung Kim, Youn-Kyung Kim, Young Eun Kim, Young Hee Kim, Young Ho Kim, Young Hun Kim, Young Hwa Kim, Young Jin Kim, Young Ju Kim, Young Mi Kim, Young Nam Kim, Young Rae Kim, Young Ree Kim, Young S Kim, Young Sam Kim, Young Sik Kim, Young Tae Kim, Young Woo Kim, Young-Bum Kim, Young-Cho Kim, Young-Chul Kim, Young-Dae Kim, Young-Eun Kim, Young-Ho Kim, Young-Hoon Kim, Young-Il Kim, Young-Im Kim, Young-Jin Kim, Young-Joo Kim, Young-Mi Kim, Young-Saeng Kim, Young-Won Kim, Young-Woo Kim, Young-Woong Kim, Young-Youn Kim, Youngchang Kim, Youngchul Kim, Youngeun Kim, Younghoon Kim, Youngjoo Kim, Youngmi Kim, Youngsin Kim, Youngsoo Kim, Youngsook Kim, Youngwoo Kim, Yu Kyeong Kim, Yu Mi Kim, Yu-Jin Kim, Yul-Ho Kim, Yuli Kim, Yumi Kim, Yun Gi Kim, Yun Hye Kim, Yun Joong Kim, Yun Seok Kim, Yun-Jin Kim, Yunjung Kim, Yunkyung Kim, Yunwoo Kim
Although low-density lipoprotein cholesterol (LDL-C) is the main lipid target for cardiovascular risk reduction, recent studies suggest that other lipid indicies are also associated with vascular even Show more
Although low-density lipoprotein cholesterol (LDL-C) is the main lipid target for cardiovascular risk reduction, recent studies suggest that other lipid indicies are also associated with vascular events. We hypothesized that the association of triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) with atherosclerotic stroke (AS) differs depending on LDL-C levels. Data prospectively collected on subjects admitted with acute ischemic stroke to a university medical center were analyzed. We divided the patients into AS and non-atherosclerotic stroke (NAS) groups and independent association of lipid parameters and genetic influences of apolipoprotein A5 (ApoA5) polymorphisms with AS were evaluated. Of 268 patients, 160 (59.7%) were classified with AS and 108 (40.3%) were classified with NAS. Vascular risk factors were more prevalent in AS patients than in those with NAS; additionally, AS patients' anthropometric indexes and laboratory findings showed that they were prone to atherosclerosis. AS was independently associated with fasting TG (OR per 10 mg/dL increase, 1.38; 95% CI, 1.16-1.64; OR for highest vs. lowest tertile, 12.85; 95% CI, 3.31-49.85), HDL-C (OR per 10 mg/dL increase, 0.61; 95% CI, 0.42-0.88; OR for lowest vs. highest tertile, 4.28; 95% CI, 1.16-15.86), and nonfasting TG (OR per 10 10 mg/dL increase, 1.25; 95% CI, 1.11-1.42; OR for highest vs. lowest tertile, 8.20; 95% CI, 1.98-33.88) only among patients with LDL <100 mg/dL. No interaction was observed between fasting and nonfasting TG and ApoA5 polymorphisms. In conclusion, fasting and nonfasting TG and HDL-C were associated with AS only when patients had low levels of LDL-C. Non-LDL-C may have an additional role in addition to the LDL-C levels in AS development. Show less
Triglyceride (TG) is a complex phenotype influenced by both genetic and environmental factors. Recent genome-wide association studies (GWAS) have identified genes or loci affecting lipid levels; howev Show more
Triglyceride (TG) is a complex phenotype influenced by both genetic and environmental factors. Recent genome-wide association studies (GWAS) have identified genes or loci affecting lipid levels; however, such studies in Chinese populations are limited. A two-stage GWAS were conducted to identify genetic variants that were associated with TG in a Chinese population of 3495 men. Gene-environment interactions on serum TG levels were further investigated for the seven single nucleotide polymorphisms (SNPs) that were studied in both stages. Two previously reported SNPs (rs651821 in APOA5, rs328 in LPL) were replicated in the second stage, and the combined P-values were 9.19 × 10(-26) and 1.41 × 10(-9) for rs651821 and rs328, respectively. More importantly, a significant interaction between aldehyde dehydrogenase 2 (ALDH2) rs671 and alcohol consumption on serum TG levels were observed (P = 3.34 × 10(-5)). Rs671 was significantly associated with serum TG levels in drinkers (P = 1.90 × 10(-10)), while no association was observed in non-drinkers (P > 0.05). For drinkers, men carrying the AA/AG genotype have significantly lower serum TG levels, compared with men carrying the GG genotype. For men with the GG genotype, the serum TG levels increased with the quantity of alcohol intake (P = 1.28 × 10(-8) for trend test). We identified a novel, significant interaction effect between alcohol consumption and the ALDH2 rs671 polymorphism on TG levels, which suggests that the effect of alcohol intake on TG occurs in a two-faceted manner. Just one drink can increase TG level in susceptible individuals who carry the GG genotype, while individuals carrying AA/AG genotypes may actually benefit from moderate drinking. Show less
Apolipoprotein A5 (APOA5) was identified as a strong modulator of serum lipids. Moreover, an APOA5 gene -1131T>C polymorphism has been associated with serum lipids, but the results are inconsistent ac Show more
Apolipoprotein A5 (APOA5) was identified as a strong modulator of serum lipids. Moreover, an APOA5 gene -1131T>C polymorphism has been associated with serum lipids, but the results are inconsistent according to ethnic and racial groups. We have genotyped and analyzed 1,619 outpatients of Korean oriental medicine hospitals who were classified into three Sasang constitution groups (SCGs), So-Yang (SY), So-Eum (SE), and Tae-Eum (TE). There were no significant difference in the distribution of the APOA5 -1131T>C genotype among the three SCGs. Subjects with the C allele in SY and TE showed significantly lower serum high-density lipoprotein cholesterol (HDL-C) and higher triglyceride (TG) levels than noncarriers of the C allele. These results show the differences in the prevalence of decreasing serum HDL-C and elevating serum TG levels along with APOA5 -1131T>C polymorphism according to SCG and suggest that SCG may act as a significant risk factor for hypo-HDL-C-emia and hypertriglyceridemia susceptibility. Show less
Recently, the single nucleotide polymorphism (SNP) identified as rs1260326, in the glucokinase regulatory protein (GCKR), was associated with hypertriglyceridemia in adults. Because accumulation of tr Show more
Recently, the single nucleotide polymorphism (SNP) identified as rs1260326, in the glucokinase regulatory protein (GCKR), was associated with hypertriglyceridemia in adults. Because accumulation of triglycerides in hepatocytes represents the hallmark of steatosis, we aimed to investigate whether this variant might be associated with fatty liver (hepatic fat content, HFF%). Moreover, because recently rs738409 in the PNPLA3 and rs2854116 in the APOC3 were associated with fatty liver, we explored how the GCKR SNP and these two variants jointly influence hepatosteatosis. We studied 455 obese children and adolescents (181 Caucasians, 139 African Americans, and 135 Hispanics). All underwent an oral glucose tolerance test and fasting lipoprotein subclasses measurement by proton nuclear magnetic resonance. A subset of 142 children underwent a fast gradient magnetic resonance imaging to measure the HFF%. The rs1260326 was associated with elevated triglycerides (Caucasians P = 0.00014; African Americans P = 0.00417), large very low-density lipoprotein (VLDL) (Caucasians P = 0.001; African Americans, P = 0.03), and with fatty liver (Caucasians P = 0.034; African Americans P = 0.00002; and Hispanics P = 0.016). The PNPLA3, but not the APOC3 rs2854116 SNP, was associated with fatty liver but not with triglyceride levels. There was a joint effect between the PNPLA3 and GCKR SNPs, explaining 32% of HFF% variance in Caucasians (P = 0.00161), 39.0% in African Americans (P = 0.00000496), and 15% in Hispanics (P = 0.00342). The rs1260326 in GCKR is associated with hepatic fat accumulation along with large VLDL and triglyceride levels. GCKR and PNPLA3 act together to convey susceptibility to fatty liver in obese youths. Show less
Centriolar satellites are PCM-1-positive granules surrounding centrosomes. Proposed functions of the centriolar satellites include protein targeting to the centrosome, as well as communication between Show more
Centriolar satellites are PCM-1-positive granules surrounding centrosomes. Proposed functions of the centriolar satellites include protein targeting to the centrosome, as well as communication between the centrosome and surrounding cytoplasm. CEP90 is a centriolar satellite protein that is critical for spindle pole integrity in mitotic cells. In this study, we examined the biological functions of CEP90 in interphase cells. CEP90 physically interacts with PCM-1 at centriolar satellites, and this interaction is essential for centrosomal accumulation of the centriolar satellites and eventually for primary cilia formation. CEP90 is also required for BBS4 loading on centriolar satellites and its localization in primary cilia. Our results imply that the assembly and transport of centriolar satellites are critical steps for primary cilia formation and ciliary protein recruitment. Show less
Sung Hee Park, Sangsoo Kim · 2012 · International journal of data mining and bioinformatics · added 2026-04-24
Genome-wide association studies (GWAS) have served crucial roles in investigating disease susceptible loci for single traits. On the other hand, GWAS have been limited in measuring genetic risk factor Show more
Genome-wide association studies (GWAS) have served crucial roles in investigating disease susceptible loci for single traits. On the other hand, GWAS have been limited in measuring genetic risk factors for multivariate phenotypes from pleiotropic genetic effects of genetic loci. This work reports a data mining approach to discover patterns of multivariate phenotypes expressed as association rules, and presents an analytical scheme for GWAS of those newly defined multivariate phenotypes. We identified 13 SNPs for four genes (CSMD1, NFE2L1, CBX1, and SKAP1) associated with a new multivariate phenotype defined as low levels of low density lipoprotein cholesterol (LDL-C < or = 100 mg/dl) and high levels of triglycerides (TG > or = 180 mg/dl). Compared with a traditional approach to GWAS, the use of discovered multivariate phenotypes can be advantageous in identifying pleiotropic genetic risk factors, which may have a common etiological role for the multivariate phenotypes. Show less
Batten disease is an inherited disorder characterized by early onset neurodegeneration due to the mutation of the CLN3 gene. The function of the CLN3 protein is not clear, but an association with oxid Show more
Batten disease is an inherited disorder characterized by early onset neurodegeneration due to the mutation of the CLN3 gene. The function of the CLN3 protein is not clear, but an association with oxidative stress has been proposed. Oxidative stress and DNA damage play critical roles in the pathogenesis of neurodegenerative diseases. Antioxidants are of interest because of their therapeutic potential for treating neurodegenerative diseases. We tested whether N-acetylcysteine (NAC), a well-known antioxidant, improves the pathology of cells from patients with Batten disease. At first, the expression levels of urea cycle components and DNA repair enzymes were compared between Batten disease cells and normal cells. We used both mRNA expression levels and Western blot analysis. We found that carbamoyl phosphate synthetase 1, an enzyme involved in the urea cycle, 8-oxoguanine DNA glycosylase 1 and DNA polymerase beta, enzymes involved in DNA repair, were expressed at higher levels in Batten disease cells than in normal cells. The treatment of Batten disease cells with NAC for 48 h attenuated activities of the urea cycle and of DNA repair, as indicated by the substantially decreased expression levels of carbamoyl phosphate synthetase 1, 8-oxoguanine DNA glycosylase 1 and DNA polymerase beta proteins compared with untreated Batten cells. NAC may serve in alleviating the burden of urea cycle and DNA repair processes in Batten disease cells. We propose that NAC may have beneficial effects in patients with Batten disease. Show less
p53 regulates various cellular responses through transcriptional regulation of distinct sets of target genes. Dual specificity phosphatase 6 (DUSP6) is a cytosolic phosphatase that inactivates the ext Show more
p53 regulates various cellular responses through transcriptional regulation of distinct sets of target genes. Dual specificity phosphatase 6 (DUSP6) is a cytosolic phosphatase that inactivates the extracellular-signal-regulated kinase 1/2 (ERK1/2). This study demonstrates that p53 transactivates DUSP6 in human colorectal HCT116 cells to regulate ERK1/2 in p53-mediated cell death. DUSP6 is transactivated by p53 overexpression and genotoxic agents, and chromatin immunoprecipitation revealed two p53-binding sites in the DUSP6 promoter responsible for DUSP6 induction. Expression of shDUSP6 inhibited 5'-FU-induced cell death, whereas overexpression of DUSP6 increased susceptibility to 5'-FU. 5'-FU treatment dephosphorylated ERK in a DUSP6-dependent manner, resulting in destabilization of Bcl-2 and stabilization of Bad. These results provide insights on the modulatory role of p53 in the survival pathway by up-regulating DUSP6. Show less
The effects of antipsychotics on various gene expressions through change in DNA methylation have been reported. Dual-specificity phosphatase 6 (DUSP6) is an extracellular signal regulated kinase 1/2 ( Show more
The effects of antipsychotics on various gene expressions through change in DNA methylation have been reported. Dual-specificity phosphatase 6 (DUSP6) is an extracellular signal regulated kinase 1/2 (ERK1/2)-selective phosphatase, and its expression can be suppressed by intronic methylation. Antipsychotic agent haloperidol affects ERK1/2 activity and could induce changes in DNA methylation as well as histone acetylation. In this study, we examined the effects of haloperidol on DUSP6 expression related to DNA methylation changes. The effects of haloperidol and 5-azacytidine, a demethylating agent, on expression and methylation of DUSP6 were quantitatively measured in MIA PaCa-2 human pancreatic carcinoma cells, in which DUSP6 expression is suppressed due to intronic hypermethylation. The growth rate of MIA PaCa-2 cells was also examined after treatment with haloperidol or 5-azacytidine. Haloperidol increased DUSP6 expression in a concentration-dependent manner and inhibited MIA PaCa-2 cell proliferation; effects were comparable to those of 5-azacytidine. However, haloperidol did not induce DUSP6 expression in PANC-1 cells, another pancreatic cancer cell line without transcriptional suppression of DUSP6. Pyrosequencing methylation analysis confirmed the intronic hypermethylation of DUSP6 in MIA PaCa-2 and revealed that haloperidol and 5-azcytidine induced demethylation of CpG sequences in this region. Haloperidol induced DUSP6 expression related to intronic demethylation and inhibited MIA PaCa-2 cell proliferation, which suggests demethylating activity and anti-cancer effects of haloperidol. These findings suggest the possible involvement of epigenetic regulatory mechanisms in the action mechanism of haloperidol. Show less
Activation of extracellular signal-related kinase (ERK) is involved in decreased melanogenesis by sphingosylphosphorylcholine (SPC). In the present study, we confirmed that SPC activated ERK and that Show more
Activation of extracellular signal-related kinase (ERK) is involved in decreased melanogenesis by sphingosylphosphorylcholine (SPC). In the present study, we confirmed that SPC activated ERK and that a specific inhibitor of the ERK pathway (PD98059) recovered SPC-induced hypopigmentation. Moreover, we found that SPC significantly reduces protein phosphatase 2A (PP2A) activity in Mel-Ab cells, and that PP2A activator treatment abrogated SPC-induced hypopigmentation. We determined that α-melanocyte-stimulating hormone (α-MSH) increased the expression of dual-specificity phosphatase 6 (DUSP6), an ERK phosphatase, in a time-dependent manner. In contrast, SPC decreased the level of DUSP6 in Mel-Ab cells. Furthermore, inhibiting DUSP6 increased ERK activation and subsequently augmented the SPC-induced hypopigmenting effects. Taken together, our data suggest that SPC-induced phosphatase inhibition is also responsible for the hypopigmentary effects. Show less
The genetic mutations causing the constitutive activation of MEK/ERK have been regarded as an initiating factor in papillary thyroid carcinoma (PTC). The ERK-specific dual specificity phosphatase 6 (D Show more
The genetic mutations causing the constitutive activation of MEK/ERK have been regarded as an initiating factor in papillary thyroid carcinoma (PTC). The ERK-specific dual specificity phosphatase 6 (DUSP6) is part of the ERK-dependent transcriptional output. Therefore, the coordinated regulation of the activities of ERK kinases and DUSP6 may need to be reestablished to make new balances in PTC. To investigate the role of DUSP6 in the regulation of ERK1/2 (MAPK3/1)-dependent transcription, 42 benign neoplasms and 167 PTCs were retrospectively analyzed by immunohistochemistry with dideoxy sequencing to detect BRAF(V600E) mutation. The expressions of total ERK1/2, DUSP6, c-Fos (FOS), c-Myc (MYC), cyclin D1, and PCNA were markedly increased in PTC compared with those in benign neoplasms. However, phospho-ERK1/2 was detected in only eight (4.8%) cases out of 167 PTC samples. Unexpectedly, the staining intensity and nuclear localization of ERK1/2 were not affected by the presence or absence of the BRAF(V600E) mutation. However, the expressions of c-Fos and PCNA were elevated in BRAF(V600E)-positive PTC compared with those in BRAF(V600E)-negative PTC. Interestingly, the higher staining intensities of DUSP6 were associated with the level of total ERK1/2 expression (P=0.04) and with high-risk biological features such as age (P=0.05), tumor size (P=0.01), and extrathyroidal extension (linear by linear association, P=0.02). In addition, DUSP6 silencing significantly decreased the cell viability and migration rate of FRO cells. The coordinated upregulation of total ERK1/2 and its phosphatase, DUSP6, is related to bare detection of phospho-ERK1/2 in PTC regardless of BRAF(V)(600E) mutation status. A link between DUSP6 expression and high-risk features of PTC suggested that DUSP6 is an important independent factor affecting the signaling pathways in established PTC. Show less
Cisplatin is an effective anticancer drug used to treat many types of cancer, including non-small cell lung carcinoma (NSCLCs), but development of resistance is the primary impediment in cancer treatm Show more
Cisplatin is an effective anticancer drug used to treat many types of cancer, including non-small cell lung carcinoma (NSCLCs), but development of resistance is the primary impediment in cancer treatment. Insulin-like growth factor-binding protein 7 (IGFBP7) is a secreted tumor suppressor that is inactivated in human lung cancer. IGFBP7 is known to alter sensitivity to interferon-based anticancer therapy, and here, we examined loss of IGFBP7 as a potential contributor to chemo-resistance to cisplatin. The transcriptional level of IGFBP7 was decreased in cisplatin-resistant human cancer cell lines and NSCLC xenografts. IGFBP7 knock-down increased cellular resistance to cisplatin and increased the level of mitogen-activated protein kinase phosphatases (MKP) 3 levels. The expression of MKP3 increased in a cisplatin-resistant NSCLC cell line and lung xenografts. MKP3 knock-down increased IGFBP7 level, indicating that MKP3 regulates IGFBP7. These findings suggest a novel molecular mechanism responsible for the tumor suppressive function of IGFBP7 in cisplatin-resistant human lung cancer and could lead to the development of IGFBP7 as a cisplatin-sensitizing agent. Show less
The dual-specificity phosphatase 6 (DUSP6) gene resides at chromosome location 12q22-23, which is one of the candidate loci for susceptibility to bipolar disorder and which encodes a phosphatase selec Show more
The dual-specificity phosphatase 6 (DUSP6) gene resides at chromosome location 12q22-23, which is one of the candidate loci for susceptibility to bipolar disorder and which encodes a phosphatase selective for extracellular signal-regulated kinase (ERK). Previously, we reported a positive association between the functional Leu114Val polymorphism (rs2279574) in DUSP6 and bipolar disorder. Given that the association between DUSP6 and the reported down-regulation of DUSP6 transcript in bipolar postmortem brains were sex-dimorphic, showing significance in women but not men, we performed two independent analyses in homogenous samples of male and female Korean patients with bipolar disorder or schizophrenia using samples enlarged from our previous report. Among the examined DUSP6 SNPs, five (rs769700, rs704076, rs770087, rs808820, and rs2279574) showed positive allelic associations, with the frequency of minor alleles (C, T, G, G, and G) in each SNP significantly increased in women with BD. Consequently, the "C-T-G-G-G" haplotype was significantly over-represented (P=0.016; OR=3.242), whereas the "T-G-T-A-T" haplotype was significantly under-represented (P=0.014; OR=0.697). We found no significant associations with DUSP6 SNPs in men with bipolar disorder or schizophrenia. We also investigated the functions of the functional SNPs' positive associations and found that Leu114Val (rs2279574; T/G) and Ser144Ala (rs770087; T/G) mutations in DUSP6 proteins reduced lithium-induced ERK1/2 phosphorylation in vitro, implicating the dominant active functions. Thus, DUSP6 may not only play important roles in the pathogenesis of bipolar disorder, particularly in women, but also affect the therapeutic response to lithium through modulating lithium's effects on intracellular signaling. Show less
The fatty acid desaturase genes (FADS1 and FADS2) code for enzymes required for synthesis of omega-3 and omega-6 long-chain polyunsaturated fatty acids (LCPUFA) important in the central nervous system Show more
The fatty acid desaturase genes (FADS1 and FADS2) code for enzymes required for synthesis of omega-3 and omega-6 long-chain polyunsaturated fatty acids (LCPUFA) important in the central nervous system, inflammatory response, and cardiovascular health. SNPs in these genes are associated with numerous health outcomes, but it is unclear how genetic variation affects enzyme function. Here, lymphoblasts obtained from Japanese participants in the International HapMap Project were evaluated for association of expression microarray results with SNPs in the FADS gene cluster. Six SNPs in the first intron of the FADS2 gene were associated with FADS1 expression. A 10-SNP haplotype in FADS2 (rs2727270 to rs2851682) present in 24% of the population was associated with lower expression of FADS1. A highly conserved region coinciding with the most significant SNPs contained predicted binding sites for SREBP and PPARγ. Lymphoblasts homozygous for either the major or minor haplotype were treated with agonists for these transcription factors and expression of FADS1 and FADS2 determined. Simvastatin and the LXR agonist GW3965 both upregulated expression of FADS1 and FADS2; no response was found for PPARγ agonist rosiglitazone. The minor haplotype homozygotes had 20-40% higher induction of FADS1 and FADS2 after simvastatin or GW3965 treatment. A 22 bp polymorphic insertion-deletion (INDEL) was found 137 bp downstream from the putative sterol response element, as well as a 3 or 1 bp INDEL 81-83 bp downstream. All carriers of the minor haplotype had deletions while all carriers of the major haplotype had insertions. Individuals carrying the minor haplotype may be vulnerable to alterations in diet that reduce LCPUFA intake, and especially responsive to statin or marine oil therapy. Show less
A genome-wide association study identified a strong correlation between body mass index and the presence of a 21-kb copy number variation upstream of the human GPRC5B gene; however, the functional rol Show more
A genome-wide association study identified a strong correlation between body mass index and the presence of a 21-kb copy number variation upstream of the human GPRC5B gene; however, the functional role of GPRC5B in obesity remains unknown. We report that GPRC5B-deficient mice were protected from diet-induced obesity and insulin resistance because of reduced inflammation in their white adipose tissue. GPRC5B is a lipid raft-associated transmembrane protein that contains multiple phosphorylated residues in its carboxyl terminus. Phosphorylation of GPRC5B by the tyrosine kinase Fyn and the subsequent direct interaction with Fyn through the Fyn Src homology 2 (SH2) domain were critical for the initiation and progression of inflammatory signaling in adipose tissue. We demonstrated that a GPRC5B mutant lacking the direct binding site for Fyn failed to activate a positive feedback loop of nuclear factor κB-inhibitor of κB kinase ε signaling. These findings suggest that GPRC5B may be a major node in adipose signaling systems linking diet-induced obesity to type 2 diabetes and may open new avenues for therapeutic approaches to diabetic progression. Show less
Ezh2 is a histone trimethyltransferase that silences genes mainly via catalyzing trimethylation of histone 3 lysine 27 (H3K27Me3). The role of Ezh2 as a regulator of gene silencing and cell proliferat Show more
Ezh2 is a histone trimethyltransferase that silences genes mainly via catalyzing trimethylation of histone 3 lysine 27 (H3K27Me3). The role of Ezh2 as a regulator of gene silencing and cell proliferation in cancer development has been extensively investigated; however, its function in heart development during embryonic cardiogenesis has not been well studied. In the present study, we used a genetically modified mouse system in which Ezh2 was specifically ablated in the mouse heart. We identified a wide spectrum of cardiovascular malformations in the Ezh2 mutant mice, which collectively led to perinatal death. In the Ezh2 mutant heart, the endocardial cushions (ECs) were hypoplastic and the endothelial-to-mesenchymal transition (EMT) process was impaired. The hearts of Ezh2 mutant mice also exhibited decreased cardiomyocyte proliferation and increased apoptosis. We further identified that the Hey2 gene, which is important for cardiomyocyte proliferation and cardiac morphogenesis, is a downstream target of Ezh2. The regulation of Hey2 expression by Ezh2 may be independent of Notch signaling activity. Our work defines an indispensible role of the chromatin remodeling factor Ezh2 in normal cardiovascular development. Show less
Circulating androgen levels are often used as indicators of physiological or pathological conditions. More than half of the variance for circulating androgen levels is thought to be genetically influe Show more
Circulating androgen levels are often used as indicators of physiological or pathological conditions. More than half of the variance for circulating androgen levels is thought to be genetically influenced. A genome-wide association study (GWAS) has identified two loci, SHBG at 17p13 and FAM9B at Xp22, for serum testosterone (T) levels; however, these explain only a small fraction of inter-individual variability. To identify additional genetic determinants of androgen levels, a GWAS of baseline serum T and dihydrotestosterone (DHT) levels was conducted in 3225 men of European ancestry from the REduction by DUtasteride of Prostate Cancer Events (REDUCE) study. Cross-validation was used to confirm the observed associations between the drug (n = 1581) and placebo (n = 1644) groups of REDUCE. In addition to confirming the associations of two known loci with serum T levels (rs727428 in SHBG: P = 1.26 × 10(-12); rs5934505 in FAM9B: P = 1.61 × 10(-8)), we identified a new locus, JMJD1C at 10q21 that was associated with serum T levels at a genome-wide significance level (rs10822184: P = 1.12 × 10(-8)). We also observed that the SHBG locus was associated with serum DHT levels (rs727428: P = 1.47 × 10(-11)). Moreover, two additional variants in SHBG [rs72829446, in strong linkage equilibrium with the missense variant D356N (rs6259), and rs1799941] were also independently associated with circulating androgen levels in a statistical scale. These three loci (JMJD1C, SHBG and FAM9B) were estimated to account for ~5.3 and 4.1% of the variance of serum T and DHT levels. Our findings may provide new insights into the regulation of circulating androgens and potential targets for androgen-based therapy. Show less
In liver, glucose utilization and lipid synthesis are inextricably intertwined. When glucose availability exceeds its utilization, lipogenesis increases, leading to increased intrahepatic lipid conten Show more
In liver, glucose utilization and lipid synthesis are inextricably intertwined. When glucose availability exceeds its utilization, lipogenesis increases, leading to increased intrahepatic lipid content and lipoprotein secretion. Although the fate of three-carbon metabolites is largely determined by flux rate through the relevant enzymes, insulin plays a permissive role in this process. But the mechanism integrating insulin receptor signaling to glucose utilization with lipogenesis is unknown. Forkhead box O1 (FoxO1), a downstream effector of insulin signaling, plays a central role in hepatic glucose metabolism through the regulation of hepatic glucose production. In this study, we investigated the mechanism by which FoxO1 integrates hepatic glucose utilization with lipid synthesis. We show that FoxO1 overexpression in hepatocytes reduces activity of carbohydrate response element binding protein (Chrebp), a key regulator of lipogenesis, by suppressing O-linked glycosylation and reducing the protein stability. FoxO1 inhibits high glucose- or O-GlcNAc transferase (OGT)-induced liver-pyruvate kinase (L-PK) promoter activity by decreasing Chrebp recruitment to the L-PK promoter. Conversely, FoxO1 ablation in liver leads to the enhanced O-glycosylation and increased protein level of Chrebp owing to decreased its ubiquitination. We propose that FoxO1 regulation of Chrebp O-glycosylation is a mechanism linking hepatic glucose utilization with lipid synthesis. Show less
Non-alcoholic fatty liver disease (NAFLD) and pathological adiposity has emerged as an important modern disease. Along with this, the requirement for alternative and natural medicine for preventing NA Show more
Non-alcoholic fatty liver disease (NAFLD) and pathological adiposity has emerged as an important modern disease. Along with this, the requirement for alternative and natural medicine for preventing NAFLD and adiposity has been increasing rapidly and considerably. In this report, we will review the biological effect and mechanisms of soy isoflavones on NAFLD and pathologic adiposity mainly through the novel pathways, de novo lipogenic carbohydrate responsive element binding protein (ChREBP) and anti-adipogenic Wnt signaling. This paper reviews in vitro and in vivo isoflavone studies published in 2002 to 2011 in North America and East Asia. Collectively, the data support a beneficial relation of isoflavones and NAFLD and/or adiposity. Isoflavones suppress ChREBP signaling via protein kinase A (PKA) and/or 5'-AMP activated protein kinase (AMPK)-dependent phosphorylation, which prevents ChREBP from binding to the promoter regions of lipogenic enzyme. Furthermore, isoflavones directly stimulate Wnt signaling via estrogen receptors-dependent pathway, which inactivates glycogen synthase kinase-3 beta (GSK-3β), transactivate T-cell factor/lymphoid-enhancer factor (TCF/LEF), the effector of Wnt signaling, degrade adipogenic peroxisome proliferator-activated receptor γ (PPARγ), augment p300/CBP, the transcriptional co-activators of TCF/LEF. Natural compound isoflavones may be useful alternative medicines in preventing NAFLD and pathological adiposity and this action may be partially associated with ChREBP and Wnt signaling. Show less
Chronic kidney disease (CKD) is an important public health problem with a genetic component. We performed genome-wide association studies in up to 130,600 European ancestry participants overall, and s Show more
Chronic kidney disease (CKD) is an important public health problem with a genetic component. We performed genome-wide association studies in up to 130,600 European ancestry participants overall, and stratified for key CKD risk factors. We uncovered 6 new loci in association with estimated glomerular filtration rate (eGFR), the primary clinical measure of CKD, in or near MPPED2, DDX1, SLC47A1, CDK12, CASP9, and INO80. Morpholino knockdown of mpped2 and casp9 in zebrafish embryos revealed podocyte and tubular abnormalities with altered dextran clearance, suggesting a role for these genes in renal function. By providing new insights into genes that regulate renal function, these results could further our understanding of the pathogenesis of CKD. Show less
The present study reports a novel liver X receptor (LXR) activator, ethyl 2,4,6-trihydroxybenzoate (ETB), isolated from Celtis biondii. Using a reporter gene assay, time-resolved fluorescence resonanc Show more
The present study reports a novel liver X receptor (LXR) activator, ethyl 2,4,6-trihydroxybenzoate (ETB), isolated from Celtis biondii. Using a reporter gene assay, time-resolved fluorescence resonance energy transfer (TR-FRET), and surface plasmon resonance (SPR) analysis, we showed that ETB directly bound to and stimulated the transcriptional activity of LXR-α and LXR-β. In macrophages, hepatocytes, and intestinal cells, ETB suppressed cellular cholesterol accumulation in a dose-dependent manner and induced the transcriptional activation of LXR-α/-β-responsive genes. Notably, ETB did not induce lipogenic gene expression or cellular triglyceride accumulation in hepatocytes. These results suggest that ETB is a dual-LXR modulator that regulates the expression of key genes in cholesterol homeostasis in multiple cells without inducing lipid accumulation in HepG2 cells. Show less
Chiara Gabbi, Xiaomu Kong, Hitoshi Suzuki+8 more · 2012 · Proceedings of the National Academy of Sciences of the United States of America · National Academy of Sciences · added 2026-04-24
The present study demonstrates a key role for the oxysterol receptor liver X receptor β (LXRβ) in the etiology of diabetes insipidus (DI). Given free access to water, LXRβ(-/-) but not LXRα(-/-) mice Show more
The present study demonstrates a key role for the oxysterol receptor liver X receptor β (LXRβ) in the etiology of diabetes insipidus (DI). Given free access to water, LXRβ(-/-) but not LXRα(-/-) mice exhibited polyuria (abnormal daily excretion of highly diluted urine) and polydipsia (increased water intake), both features of diabetes insipidus. LXRβ(-/-) mice responded to 24-h dehydration with a decreased urine volume and increased urine osmolality. To determine whether the DI was of central or nephrogenic origin, we examined the responsiveness of the kidney to arginine vasopressin (AVP). An i.p. injection of AVP to LXRβ(-/-) mice revealed a partial kidney response: There was no effect on urine volume, but there was a significant increase of urine osmolality, suggesting that DI may be caused by a defect in central production of AVP. In the brain of WT mice LXRβ was expressed in the nuclei of magnocellular neurons in the supraoptic and paraventricular nuclei of the hypothalamus. In LXRβ(-/-) mice the expression of AVP was markedly decreased in the magnocellular neurons as well as in urine collected over a 24-h period. The persistent high urine volume after AVP administration was traced to a reduction in aquaporin-1 expression in the kidney of LXRβ(-/-) mice. The LXR agonist (GW3965) in WT mice elicited an increase in urine osmolality, suggesting that LXRβ is a key receptor in controlling water balance with targets in both the brain and kidney, and it could be a therapeutic target in disorders of water balance. Show less
There is increasing evidence that the retinoic acid receptor-related orphan receptor α (RORα) plays an important role in the regulation of metabolic pathways, particularly of fatty acid and cholestero Show more
There is increasing evidence that the retinoic acid receptor-related orphan receptor α (RORα) plays an important role in the regulation of metabolic pathways, particularly of fatty acid and cholesterol metabolism; however, the role of RORα in the regulation of hepatic lipogenesis has not been studied. Here, we report that RORα attenuates hepatic steatosis, probably via activation of the adenosine monophosphate (AMP)-activated protein kinase (AMPK) and repression of the liver X receptor α (LXRα). First, RORα and its activator, cholesterol sulfate (CS), induced phosphorylation of AMPK, which was accompanied by the activation of serine-threonine kinase liver kinase B1 (LKB1). Second, the activation of RORα, either by transient transfection or CS treatment, decreased the TO901317-induced transcriptional expression of LXRα and its downstream target genes, such as the sterol regulatory element binding protein-1 (SREBP-1) and fatty acid synthase. RORα interacted physically with LXRα and inhibited the LXRα response element in the promoter of LXRα, indicating that RORα interrupts the autoregulatory activation loop of LXRα. Third, infection with adenovirus encoding RORα suppressed the lipid accumulation that had been induced by a free-fatty-acid mixture in cultured cells. Furthermore, we observed that the level of expression of the RORα protein was decreased in the liver of mice that were fed a high-fat diet. Restoration of RORα via tail-vein injection of adenovirus (Ad)-RORα decreased the high-fat-diet-induced hepatic steatosis. Finally, we synthesized thiourea derivatives that activated RORα, thereby inducing activation of AMPK and repression of LXRα. These compounds decreased hepatic triglyceride levels and lipid droplets in the high-fat-diet-fed mice. We found that RORα induced activation of AMPK and inhibition of the lipogenic function of LXRα, which may be key phenomena that provide the beneficial effects of RORα against hepatic steatosis. Show less
The mitogen-activated kinases JNK1/2/3 are key enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response. Here, we report the discovery of irre Show more
The mitogen-activated kinases JNK1/2/3 are key enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response. Here, we report the discovery of irreversible inhibitors of JNK1/2/3. We describe two JNK3 cocrystal structures at 2.60 and 2.97 Å resolution that show the compounds form covalent bonds with a conserved cysteine residue. JNK-IN-8 is a selective JNK inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue. Extensive biochemical, cellular, and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggests that the compound will be broadly useful as a pharmacological probe of JNK-dependent signal transduction. Potential lead compounds have also been identified for kinases, including IRAK1, PIK3C3, PIP4K2C, and PIP5K3. Show less
Breast cancer is one of the most common types of cancer in women and is highly treatable by radiotherapy. However, repeated exposure to radiation results in tumor cell resistance. Understanding the mo Show more
Breast cancer is one of the most common types of cancer in women and is highly treatable by radiotherapy. However, repeated exposure to radiation results in tumor cell resistance. Understanding the molecular mechanisms involved in the response of tumors to γ-irradiation is important for improving radiotherapy. For this reason, we aimed to identify radiation-responsive genes at the protein level. In the present study, we observed differentially expressed proteins using 2D-PAGE and MALDI-TOF-MS for the global analysis of protein expression patterns in response to ionizing radiation (IR). When the expression patterns of proteins were compared to a control gel, numerous spots were found that differed greatly. Among them, 11 spots were found to be significantly different. One set of proteins (GH2, RGS17, BAK1, CCNH, TSG6, RAD51B, IGFBP1 and CASP14) was upregulated and another set of proteins (C1QRF, PLSCR2 and p34(SE1-1)) was downregulated after exposure to γ-rays. These proteins are known to be related to cell cycle control, apoptosis, DNA repair, cell proliferation and other signaling pathways. Show less
Diseases related to smoking are the second leading cause of death in the world. Cigarette smoking is a risk factor for several diseases such as cancer and cardiovascular and respiratory disorders. Des Show more
Diseases related to smoking are the second leading cause of death in the world. Cigarette smoking is a risk factor for several diseases such as cancer and cardiovascular and respiratory disorders. Despite increasing evidence of genetic determination, the susceptibility genes and loci underlying various aspects of smoking behavior are largely unknown. Moreover, almost all reported genome-wide association studies (GWASs) have been performed on samples of European origin, limiting the applicability of the results to other ethnic populations. In this first GWAS on smoking behavior in an Asian population, after analyzing 8,842 DNA samples from the Korea Association Resource project with 352,228 single nucleotide polymorphisms (SNPs) genotyped for each sample, we identified 8 SNPs significantly associated with smoking initiation (SI) and 4 with nicotine dependence (ND). Because of the current unavailability of an independent Asian smoking sample, we replicated the discoveries in independent samples of European-American and African-American origin. Of the 12 SNPs examined in the replicated samples, we identified two SNPs, in the regulator of G-protein signaling 17 gene (rs7747583, p value(meta) = 6.40 × 10(-6); rs2349433, p value(meta) = 5.57 × 10(-6)), associated with SI. Also, we found two SNPs significantly associated with ND; one in the FERM domain containing 4A (rs4424567, p value(meta) = 2.30 × 10(-6)) and the other at 7q31.1 (rs848353, p value(meta) = 9.16 × 10(-8)). These SNPs represent novel targets for examination of smoking behavior and warrant further investigation using independent samples. Show less
The objectives of this study were to synthesize and characterize two types of cytarabine (Ara-C) lipid produgs and evaluate the prodrugs for sustained intraocular delivery after administration by intr Show more
The objectives of this study were to synthesize and characterize two types of cytarabine (Ara-C) lipid produgs and evaluate the prodrugs for sustained intraocular delivery after administration by intravitreal injection. Hexadecyloxypropyl cytarabine 5'-monophosphate (HDP-P-Ara-C) and hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate (HDP-cP-Ara-C) were synthesized starting from cytarabine (1-β-D-arabinofuranosylcytosine). Their vitreal clearance profile was simulated using a custom dissolution chamber, in vitro cytotoxicity was evaluated using cell proliferation assays, and in vivo ocular properties in rat and rabbit eyes were assessed using biomicroscopy, indirect ophthalmoscopy, tonometry, electroretinography, and histology. HDP-P-Ara-C was cleared from the dissolution chamber (flow rate 2 µL/min) within 7 days. In contrast, HDP-cP-Ara-C, a much more insoluble prodrug, was still detectable 36 days after the dissolution process was started. HDP-P-Ara-C had a 50% cytotoxicity concentration of 52±2.6 μM in human retinal pigment epithelium (ARPE-19) and 32±2.2 µM in a rat Müller cell line, rMC-1. The 50% cytotoxicity concentration values for HDP-cP-Ara-C in ARPE-19 and rMC-1 cells were 50 µM and 25 µM, respectively. HDP-P-Ara-C was not detectable 2 weeks after the highest intravitreal dose (228 µg/rat eye) was injected, and no ocular toxicity was found. With HDP-cP-Ara-C, the drug depot was visible for 26 weeks following a single intravitreal injection (800 µg/rabbit eye). For both compounds, the electroretinogram, intraocular pressure, and other toxicity studies were negative except for the highest dose of HDP-cP-Ara-C (800 µg/eye), which had focal toxicity from the direct touch of the retina and decreased dark adapted a-waves and decreased flicker electroretinogram amplitudes (generalized estimating equations, p=0.039 and 0.01). The cyclic monophosphate prodrug, HDP-cP-Ara-C, was found to have physiochemical properties better suited for sustained delivery of cytarabine to posterior segments of the eye. These properties included limited aqueous solubility, in vitro antiproliferative activity, and good tolerability after injection into rabbit eyes. Show less
Vacuolar protein sorting plays crucial roles in the traffic of molecules between cellular organelles. Although involvement of vacuolar protein sorting proteins in cancer is known, genetic alterations Show more
Vacuolar protein sorting plays crucial roles in the traffic of molecules between cellular organelles. Although involvement of vacuolar protein sorting proteins in cancer is known, genetic alterations of VPS genes have not been reported in cancers. We found that VPS4B, VPS13A, VPS13B, VPS13C, VPS33A, VPS35, VPS37B, VPS37D, VPS41, and VPS54 have mononucleotide repeats in their coding sequences. To see whether these genes are mutated in cancers with microsatellite instability, we analyzed the mononucleotide repeats in 30 gastric cancers with high microsatellite instability, 13 gastric cancers with low microsatellite instability, and 45 gastric cancers with stable microsatellites and 40 colorectal cancers with high microsatellite instability, 14 colorectal cancers with low microsatellite instability, and 45 colorectal cancers with stable microsatellites by single-strand conformation polymorphism. We found mutations of VPS13A, VPS13B, VPS13C, VPS33A, VPS35, VPS37B, VPS41, and VPS54 in 9, 3, 12, 3, 5, 9, 2, and 2 cancers, respectively, all in cancers with high microsatellite instability. The gastric cancers and colorectal cancers with high microsatellite instability harbored one or more mutations of the VPS genes in 53.3% and 50.0%, respectively. Loss of Vps13A expression was observed in 30% of the gastric cancers and 35% of the colorectal cancers, whereas loss of Vps35 was observed in 55% of the gastric cancers and 55% of the colorectal cancers. Our data indicate that frameshift mutations of VPS genes and losses of expression of Vps13A and Vps35 proteins are common in gastric cancers and colorectal cancers with high microsatellite instability and suggest that these alterations might contribute to development of cancers with high microsatellite instability by deregulating vacuolar protein sorting proteins. Show less
To determine whether the exogenous expression of glutathione reductase (GR) from Brassica rapa subsp. pekinensis (BrGR) can reduce the deleterious effects of unfavorable conditions, we constructed a t Show more
To determine whether the exogenous expression of glutathione reductase (GR) from Brassica rapa subsp. pekinensis (BrGR) can reduce the deleterious effects of unfavorable conditions, we constructed a transgenic Saccharomyces cerevisiae strain bearing the GR gene cloned into the yeast expression vector, pVTU260. BrGR expression was confirmed by semi reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, immunoblotting analysis and an enzyme assay. Ectopic BrGR-expression improved cellular glutathione (GSH) homeostasis after higher GSH accumulation in the transgenic yeast than in the wild-type yeast under H(2)O(2)-induced oxidative stress. The BrGR-expressing yeast strain induced the activation of metabolic enzymes (Hxt, G6PDH, GAPDH and Ald), antioxidant systems (Gpx, Trx2, Trx3, Trr1, Tsa1 and porin) and molecular chaperones (Hsp104, Hsp90, Hsp70, Hsp42, Hsp26, Grp, Sti1 and Zpr1), which led to lower oxidative protein damage after a reduction in the level of cellular ROS in the BrGR-expressing yeast strain exposed to H(2)O(2) than in the wild-type yeast strain. BrGR-expression increased the ability to adapt and recover from H(2)O(2)-induced oxidative stress and various stressors, including heat shock, menadione, tert-butyl hydroperoxide, heavy metals, sodium dodecyl sulfate, ethanol and NaCl, but did not affect fermentation capacity. These results suggest that ectopic BrGR expression confers acquired tolerance by improving proteostasis and redox homeostasis through co-activation of various cell rescue proteins against ROS-induced oxidative stress in yeast cells. Show less
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that exerts insulinotropic and growth and survival effects on pancreatic β-cells. Additionally, there is increasing evi Show more
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that exerts insulinotropic and growth and survival effects on pancreatic β-cells. Additionally, there is increasing evidence supporting an important role for GIP in the regulation of adipocyte metabolism. In the current study we examined the molecular mechanisms involved in the regulation of GIP receptor (GIPR) expression in 3T3-L1 cells. GIP acted synergistically with insulin to increase neutral lipid accumulation during progression of 3T3-L1 preadipocytes to the adipocyte phenotype. Both GIPR protein and mRNA expression increased during 3T3-L1 cell differentiation, and this increase was associated with upregulation of nuclear levels of sterol response element binding protein 1c (SREBP-1c) and peroxisome proliferator-activated receptor γ (PPARγ), as well as acetylation of histones H3/H4. The PPARγ receptor agonists LY171883 and rosiglitazone increased GIPR expression in differentiated 3T3-L1 adipocytes, whereas the antagonist GW9662 ablated expression. Additionally, both PPARγ and acetylated histones H3/H4 were shown to bind to a region of the GIPR promoter containing the peroxisome proliferator response element (PPRE). Knockdown of PPARγ in differentiated 3T3-L1 adipocytes, using RNA interference, reduced GIPR expression, supporting a functional regulatory role. Taken together, these studies show that GIP and insulin act in a synergistic manner on 3T3-L1 cell development and that adipocyte GIPR expression is upregulated through a mechanism involving interactions between PPARγ and a GIPR promoter region containing an acetylated histone region. Show less